Condition: Healthy · Idiopathic Inflammatory Myopathies · Systemic Sclerosis · Sponsor: Xencor, Inc.
The purpose of this study is to determine the safety and tolerability of XmAb657 in healthy participants and participants with autoimmune diseases. Participants will be given XmAb657 subcutaneously (SC) by injection under the skin.
This description comes directly from the study's public registry record.
Noriko Iikuni, MD, PhD · 657-aiinfo@xencor.com
Jaime Mertz · 657-aiinfo@xencor.com
Always discuss trial participation with your own doctor first.
| Xencor Investigative Site | Melbourne, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07284797